Molecular Imaging

Until now, the $168 million facility was producing limited amounts of Mo-99, a radioisotope used in approximately 85% of all Australian nuclear medicine procedures such as SPECT scans.

A team of German researchers has found a new class of radiopharmaceuticals capable of identifying 28 types of malignant tumors, imaging them with high uptake and image contrast.

 

The U.S. Pharmacopeia (USP) recently published a new chapter outlining minimum standards for preparing, compounding, dispensing and packaging sterile and non-sterile radiopharmaceuticals that are part of state-licensed activities.

The approach uses a linear electron accelerator and naturally-occurring molybdenum-100, eliminating the need for a nuclear reactor or enriched uranium.

“The value of AI applications in medical care can only be confirmed when professional guidelines provide recommendations for their use in specific clinical settings and patient populations,” wrote Gerold Porenta, MD, PhD, in a recent commentary published in the Journal of Nuclear Medicine.

Janesville, Wisconsin-based SHINE Medical Technologies has announced an agreement with the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), gaining exclusive rights over an innovation to produce lutetium-177 (Lu-177).

Researchers have combined a new imaging technique and imaging agent which utilizes a synthesized amino acid found in scorpion venom to help illuminate brain tumors during surgery.

The U.S. Nuclear Regulatory Commission (NRC) opened a 30-day public comment period seeking feedback on its draft document outlining training and experience requirements for administrating radiopharmaceuticals requiring a written directive.

Peptide radionuclide therapy (PRRT) demonstrated long-term effectiveness in patients with malignant neuroendocrine tumors, reported authors of a study published in the Journal of Nuclear Medicine.

The joint statement—published in Thyroid—was put out by American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular Imaging and the European Thyroid Association.

Johns Hopkin’s researchers have created a PET-based approach that can direct cancer drugs to precise points in the brains of mice, according to a study published in the May 1 edition of the Journal of Nuclear Medicine. If proven effective in humans, the researchers believe their technique could help patients with difficult brain tumors, such as glioblastomas.

The prospective single-center study, published April 30 in the American Journal of Roentgenology, adds more weight to the growing literature suggesting PSMA-11’s vital role in prostate cancer management.